<qa>  What was the name of the injection that was administered by all patients who entered the Open-LPatients received one injection with incobotulinumtoxinA Xeomin or placebo at baseline. Thereafter, all patients who entered the Open-Label Extension Period OLEX received up to five injection sessions of incobotulinumtoxinA Xeomin during the OLEX period. 